MMP-1 is a (pre-)invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Grimm, Martin ^a   Lazariotou, Maria ^a   Kircher, Stefan ^b   Stuermer, Luisa ^a   Reiber, Christoph ^a   Höfelmayr, Andreas ^a   Gattenlöhner, Stefan ^c   Otto, Christoph ^a   Germer, Christoph T ^a   von Rahden, Burkhard H A ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; INTERSTITIAL COLLAGENASE; KI 67 ANTIGEN; MESSENGER RNA; TRANSCRIPTION FACTOR CDX2;

AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER CELL CULTURE; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; CELL LABELING; CELL PROLIFERATION; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; GOBLET CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; ADENOCARCINOMA; BIOPSY; ENZYMOLOGY; ESOPHAGUS TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; BIOPSY; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; PROGNOSIS;

EID: 77957775867     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-99     Document Type: Article

References (49)

1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005, 97(2):142-146. 10.1093/jnci/dji024, 15657344.
2. von Rahden BHA, HJ S. Barrett's Esophagus and Barrett's Carcinoma. Curr GERD Rep 2007, (1):125-132.
3. Spechler SJ. Clinical practice. Barrett's Esophagus. N Engl J Med 2002, 346(11):836-842. 10.1056/NEJMcp012118, 11893796.
4. Sabel MS, Pastore K, Toon H, Smith JL. Adenocarcinoma of the esophagus with and without Barrett mucosa. Arch Surg 2000, 135(7):831-835. discussion 836, 10.1001/archsurg.135.7.831, 10896378.
5. Liu GS, Gong J, Cheng P, Zhang J, Chang Y, Qiang L. Distinction between short-segment Barrett's esophageal and cardiac intestinal metaplasia. World J Gastroenterol 2005, 11(40):6360-6365.
6. Shaheen N. Is there a "Barrett's iceberg?". Gastroenterology 2002, 123(2):636-639. 10.1053/gast.2002.35134, 12145816.
7. Jamieson GG. Antireflux surgery, barrett esophagus, and adenocarcinoma: there is still room for doubt. Ann Surg 2007, 246(1):22-23. 10.1097/SLA.0b013e318070d3b7, 1899218, 17592285.
8. Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol 2008, 295(2):G211-218. 10.1152/ajpgi.90250.2008, 18556417.
9. Nowell PC. The clonal evolution of tumor cell populations. Science 1976, 194(4260):23-28. 10.1126/science.959840, 959840.
10. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle 2007, 6(19):2332-2338. 10.4161/cc.6.19.4914, 17786053.
11. Zhang HY, Spechler SJ, Souza RF. Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett 2009, 275(2):170-177. 10.1016/j.canlet.2008.07.006, 2673195, 18703277.
12. Bradbury PA, Zhai R, Hopkins J, Kulke MH, Heist RS, Singh S, Zhou W, Ma C, Xu W, Asomaning K, et al. Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis 2009, 30(5):793-798. 10.1093/carcin/bgp065, 2675656, 19321798.
13. Mroczko B, Kozlowski M, Groblewska M, Lukaszewicz M, Niklinski J, Laudanski J, Chyczewski L, Szmitkowski M. Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in the different histopathological types of esophageal cancer. Folia Histochem Cytobiol 2008, 46(4):471-478. 10.2478/v10042-008-0065-9, 19141401.
14. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998, 185(3):256-261. 10.1002/(SICI)1096-9896(199807)185:3<256::AID-PATH115>3.0.CO;2-A, 9771478.
15. Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci 2001, 114(Pt 21):3865-3872.
16. Tanioka Y, Yoshida T, Yagawa T, Saiki Y, Takeo S, Harada T, Okazawa T, Yanai H, Okita K. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer 2003, 89(11):2116-2121. 10.1038/sj.bjc.6601372, 2376843, 14647147.
17. Salmela MT, Karjalainen-Lindsberg ML, Puolakkainen P, Saarialho-Kere U. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer 2001, 85(3):383-392. 10.1054/bjoc.2001.1929, 2364078, 11487270.
18. Etoh T, Inoue H, Yoshikawa Y, Barnard GF, Kitano S, Mori M. Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness. Gut 2000, 47(1):50-56. 10.1136/gut.47.1.50, 1727967, 10861264.
19. Phillips RW, Frierson HF, Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003, 27(11):1442-1447. 10.1097/00000478-200311000-00006, 14576477.
20. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998, 85(11):1457-1459. 10.1046/j.1365-2168.1998.00940.x, 9823902.
21. Sobin LH, Ch W. UICC. TNM Classification of Malignant Tumors 2002, Springer Verlag, 6.
22. Hamilton SR, Aaltonen LA. Pathology and Genetics. Tumours of the Digestive System 2000, IARC Press, third.
23. Moons LM, Bax DA, Kuipers EJ, Van Dekken H, Haringsma J, Van Vliet AH, Siersema PD, Kusters JG. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 2004, 57(10):1063-1068. 10.1136/jcp.2003.015727, 1770465, 15452161.
24. Gattenlohner S, Waller C, Ertl G, Bultmann BD, Muller-Hermelink HK, Marx A. NCAM(CD56) and RUNX1(AML1) are up-regulated in human ischemic cardiomyopathy and a rat model of chronic cardiac ischemia. Am J Pathol 2003, 163(3):1081-1090. 1868264, 12937148.
25. Grimm M, Gasser M, Bueter M, Strehl J, Wang J, Nichiporuk E, Meyer D, Germer CT, Waaga-Gasser AM, Thalheimer A. Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases. BMC Cancer 10:82. 10.1186/1471-2407-10-82, 2838824, 20205946.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 75:457-487.
27. Cox DR. Regression models and life tables. J R Stat Soc 1972, (34):1987-2001.
28. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1):57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
29. Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002, 360(9345):1587-1589. 10.1016/S0140-6736(02)11569-8, 12443613.
30. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980, 284(5751):67-68. 10.1038/284067a0, 6243750.
31. Herszenyi L, Hritz I, Pregun I, Sipos F, Juhasz M, Molnar B, Tulassay Z. Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. World J Gastroenterol 2007, 13(5):676-682.
32. Li Y, Ma J, Guo Q, Duan F, Tang F, Zheng P, Zhao Z, Lu G. Overexpression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. Dis Esophagus 2009, 22(8):664-667. 10.1111/j.1442-2050.2008.00928.x, 19191857.
33. Li Y, Sun DL, Duan YN, Zhang XJ, Wang N, Zhou RM, Chen ZF, Wang SJ. Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol Biol Rep 37(1):197-205. 10.1007/s11033-009-9593-4, 19562509.
34. Vegh I, Santiuste AD, Colina F, Bor L, Bermejo C, Aragon A, Moran-Jimenez MJ, Gomez-Camara A, De Salamanca RE, Moreno-Gonzalez E. Relationship between biomarker expression and allelic alteration in esophageal carcinoma. J Gastroenterol Hepatol 2007, 22(12):2303-2309. 10.1111/j.1440-1746.2006.04374.x, 18031395.
35. Okazaki I, Wada N, Nakano M, Saito A, Takasaki K, Doi M, Kameyama K, Otani Y, Kubochi K, Niioka M, et al. Difference in gene expression for matrix metalloproteinase-1 between early and advanced hepatocellular carcinomas. Hepatology 1997, 25(3):580-584. 10.1002/hep.510250315, 9049202.
36. Bendardaf R, Buhmeida A, Ristamaki R, Syrjanen K, Pyrhonen S. MMP-1 (collagenase-1) expression in primary colorectal cancer and its metastases. Scand J Gastroenterol 2007, 42(12):1473-1478. 10.1080/00365520701485449, 17852862.
37. Sunami E, Tsuno N, Osada T, Saito S, Kitayama J, Tomozawa S, Tsuruo T, Shibata Y, Muto T, Nagawa H. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist 2000, 5(2):108-114. 10.1634/theoncologist.5-2-108, 10794801.
38. Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, Junquera S, Merino AM, Garcia-Muniz JL. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007, 96(6):903-911. 10.1038/sj.bjc.6603666, 2360108, 17342087.
39. Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, Mukaiya M, Hirata K, Imai K. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001, 19(4):1118-1127.
40. Inoue T, Yashiro M, Nishimura S, Maeda K, Sawada T, Ogawa Y, Sowa M, Chung KH. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med 1999, 4(1):73-77.
41. Lee CH, Liu SY, Lin MH, Chiang WF, Chen TC, Huang WT, Chou DS, Chiu CT, Liu YC. Upregulation of matrix metalloproteinase-1 (MMP-1) expression in oral carcinomas of betel quid (BQ) users: roles of BQ ingredients in the acceleration of tumour cell motility through MMP-1. Arch Oral Biol 2008, 53(9):810-818. 10.1016/j.archoralbio.2008.05.004, 18571622.
42. Leeman MF, McKay JA, Murray GI. Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 2002, 55(10):758-762. 10.1136/jcp.55.10.758, 1769766, 12354802.
43. Altadill A, Rodriguez M, Gonzalez LO, Junquera S, Corte MD, Gonzalez-Dieguez ML, Linares A, Barbon E, Fresno-Forcelledo M, Rodrigo L, et al. Liver expression of matrix metalloproteases and their inhibitors in hepatocellular carcinoma. Dig Liver Dis 2009, 41(10):740-748. 10.1016/j.dld.2009.01.016, 19372066.
44. Elnemr A, Yonemura Y, Bandou E, Kinoshita K, Kawamura T, Takahashi S, Tochiori S, Endou Y, Sasaki T. Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer. Gastric Cancer 2003, 6(1):30-38. 10.1007/s101200300004, 12673424.
45. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8(10):755-768. 10.1038/nrc2499, 18784658.
46. Heeren PA, Kloppenberg FW, Hollema H, Mulder NH, Nap RE, Plukker JT. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res 2004, 24(4):2579-2583.
47. Kerkhof M, Steyerberg EW, Kusters JG, van Dekken H, van Vuuren AJ, Kuipers EJ, Siersema PD. Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus. Cancer Biomark 2008, 4(1):1-10.
48. Shingleton WD, Hodges DJ, Brick P, Cawston TE. Collagenase: a key enzyme in collagen turnover. Biochem Cell Biol 1996, 74(6):759-775. 10.1139/o96-083, 9164646.
49. Yamashita K, Mori M, Kataoka A, Inoue H, Sugimachi K. The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer 2001, 84(2):276-282. 10.1054/bjoc.2000.1568, 2363710, 11161388.